This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
OMNY Health — a national data ecosystem that facilitates biotech and medical research — launched a data network consisting of EHR data from more than 645,000 GLP-1 users. The post New Data Network Seeks to Provide Much-Needed Info on GLP-1s appeared first on MedCity News.
Equal parts networking and curated panels covering the latest trends in healthcare investment, MedCity INVEST 2024 is the ideal event to discuss health tech, biopharma, devices and diagnostics investment opportunities. Register today!
Impact of SVB UK acquisition on European biopharma companies One Netherlands-based biopharmaceutical company anticipated that the acquisition of SVP UK would allow access to its $19 million deposit and not experience losses, noted GlobalData.
EBPT Toronto expands Eurofins BioPharma Product Testing's North American presence, offering comprehensive product testing services in Toronto. It ensures consistent quality across its network, prioritizing customer satisfaction and regulatory compliance throughout the drug development process.
The company intends to grow its Biopharma Technical Development (BioTD) capabilities and transform the lab building into a state-of-the-art biotech lab by the last quarter of 2023. Sandoz has announced it is investing €25 million in its manufacturing site in Holzkirchen, Germany, to expand its biosimilar development capabilities.
Concerns around potential antitrust issues are arising from the significant control held by the legacy PBMs and, in turn, the power of their vertically integrated networks. Legislators are calling for a closer look at the vertical consolidation of PBMs with carriers.
Working in an industry with regular cross-border manufacturing and dealing with a global network of clients means adaptability is vital to maintaining good communications, building relationships, and managing teams effectively.
Sandoz] has the only major remaining vertically-integrated production network for penicillins in Europe” Penicillins are the leading category of antibiotics worldwide, Sandoz highlighted. Launch of these new facilities help to ensure sustainable access to quality antibiotics and spearhead development of biosimilars, Sandoz noted.
With 20 years of leadership experience in the life sciences and biopharma sector, Pedersen has previously had senior leadership positions in quality assurance (QA) and quality control ( QC ), regulatory affairs as well as external manufacturing. “She There, she oversaw the entire CDMO network.
According to Laursen, the decision to break into speciality enzymes was based on a look into the future of the biopharma market and an important assessment of how the company believes it can make a genuine difference. The impact could be huge for the biopharma industry.
Boehringer Ingelheim’s R&D investments Inauguration of the new facility is an additional milestone in further development of Boehringer Ingelheim’s Biberach campus, the company’s largest R&D and biopharma site, which has over 7,000 employees. Boehringer Ingelheim has invested heavily in its R&D pipeline.
Siddique noted that four of the state’s biggest biopharma companies will be located close to the site. OU Health Stephenson Cancer Center Early Phase Clinical Trial Network. The EDA will also finance five more Oklahoma-based projects: Biomanufacturing Workforce Training Center. Oklahoma Bioscience Cluster Initiative.
Supporting European parenteral manufacture and supply Alongside expanding the company’s global parenteral product and device manufacturing network, the new facility will support the higher demand for Eli Lilly’s medicines, including its diabetes and obesity portfolio.
Significant” large-scale production capacity will consequently be added to FUJIFILM Diosynth Biotechnologies’ global network. The expansion means identical large-scale production facilities can be built in US and Europe to support integration drug manufacturing production “regardless of location”, FUJIFILM explained.
Uniting the global supply chain CPHI Barcelona serves as a vital platform for unrivalled networks and access to the global supply chain. Eligible companies classified as start-ups and active in the pharma, biopharma, digital, or medical device sectors can exhibit. There has never been a better time to attend CPHI.
A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.
Award winners will be revealed at a networking reception on the first day of CPHI Barcelona 2023, which is running from 24-26 October. CUBIC CRO Service Dr Ferrer Biopharma: GentleMist Technology IamFluidics B.V.: Are you coming to the CPHI Barcelona 2023?
American Point Biopharma owns proprietary radiopharmaceutical manufacturing facilities and maintains active relations with further manufacturers. However, companies must not only use their logistical know-how to knit well-functioning infrastructure networks but also adhere to standards that consider environmental and patient safety.
This will enable biopharmas to create a more streamlined drug development process rooted in lean process execution and higher-quality data.”. As companies began collaborating more closely with contract partners, a pioneering few invited preferred CDMOs into their quality networks.
In recent years, the biopharma market has become progressively complex. HTA agencies can assist biopharma companies at the early stages of development to ensure they are meeting the expectations of payers. As a result, payers are feeling increased pressure to make the right decisions based on the perceived value of each product.
Lines are blurring between payers and providers More and more, large integrated delivery networks and national payers are battling each other for greater control over patient costs and outcomes. Payers are responding by creating, acquiring or fortifying provider networks and healthcare clinics of their own.
Sunny White is an Editorial Advisory Board member for the Pharma Marketing Network with unique insights into how important caregivers are to the HCP/patient relationship and overall health outcomes. Extension of the patient: expanding the role of caregivers in biopharma development. Sunny White. Accessed March 12, 2022.
Spreads also vary by industry sector with clinical research organizations and contract manufacturing having the lowest gaps at 8 percent with medical device companies at the highest at almost 22 percent with biopharma (pre-commercial) following at nearly 21 percent. Get the Full Report.
With a 26-year history, Merck’s Women’s Network validates the organization’s long-term commitment to diversity and inclusion and demonstrates how integral these values are to achieving better healthcare outcomes for the patients they serve. With more than 55 locations throughout the U.S.,
Mary brings to the HBA 30 years of experience leading the strategic integration of corporate branding, marketing, health equity, inclusion, and digital innovation for biopharma, healthcare, and media companies. In 2022, she co-created Real Chemistry’s first Real Health Equity Summit “Changing Out Loud” during the J.P.
It was an opportunity to make professional connections and it definitely widened my network of people to interview or shadow. He was helpful with interview preparation and sharpening my networking skills. The coaching helped us to practice, build the confidence to network, and gain meaningful connections at our target companies.
Biopharma should pay special attention to this. You’re the gatekeeper of all communication on your platform, and participants are unlikely to network with one another independently. By contrast, when patients get together in one location under your guidance, they will likely bond and form friendships and build support networks.
Those in the biopharma industry can play a pivotal role in shortening the journey to diagnosis if they learn from patients what critical pieces had to fall into place before they were diagnosed. It’s also in these communities where biopharma finds the best opportunities to connect with their stakeholders.
Star OUTiCO candidate Extensive employer network We have cultivated relationships with a vast network of pharma, medtech, and biopharma/biotech companies, many of whom are globally recognised as market-leaders in their fields.
The biopharma industry is worse, with women only accounting for 8% of CEO roles. According to the Women in Tech Network , due to lack of role models and significant personal sacrifices they’ve had to make, women leave the tech industry at a 45% higher rate than men.
Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. They created neural networks that found multiple antibiotics from millions of candidates. According to Deloitte , 76% of biopharma companies invest in AI for clinical development.
Broadly speaking, we can categorize ML-based drug repurposing methods into four classes: classical Machine Learning, Network-based, Matrix Factorization and Deep Learning”, says Anokian. “Of Network-based approaches operate on data structured as a network (graph), where nodes are biological entities (e.g.,
That was the overarching sentiment from the experienced group of biopharma leaders that formed the panel discussion chaired by Mike Ward, Clarivate Global Head of Life Sciences and Healthcare Thought Leadership, at this year’s AngloNordic Life Science conference. Timing is everything.
healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. In a fiercely competitive U.S. Christopher Silva, Senior Healthcare Research Analyst.
Acelyrin overview Acelyrin is a biopharma company that identifies, acquires and accelerates the development and commercialization of transformative medicines.It Affibody molecules are antibody mimetics with superior characteristics surpassing monoclonal antibodies and antibody fragments. It was also under development for Takayasu arteritis.
This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. Those of us in the biopharma industry know how fraught drug development can be. As the saying goes, they are individually rare but collectively common. Many people, cumulatively, are affected.
Nearly every biopharma with a portfolio of drugs in development spanning traditional small molecules and biologics and the newer CGT operates with separate clinical supply organizations per these therapy areas. What are the general differences in the supply chain of CGT vs. traditional clinical trials?
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of stakeholders earlier than you think.
Putting pandemic-related factors aside, a significant portion of the heightened demand for CRO/CDMO services has been driven by VC-backed pharma and biopharma companies. Significantly, Scanlan states that the current industry-predicted growth rates of 7.2 percent 1 for CROs and 8.5 1 Source: Piper Sandler.
Innovative agreements can take various forms, ranging in the types and sources of clinical outcomes and forms of financial risk sharing (i.e., rebates, paybacks, or earned payments) (Figure 1).
In three short years, Kite has grown to be the largest CAR T-cell therapy company in the world, with an extensive in-house manufacturing network devoted to creating this specialized treatment for patients. In addition to serving as an advocate for patients, Christi has been a role model and mentor for women throughout her career.
With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.
So, a key starting point is to study this vertical carefully and learn about the various roles each of its segments (and others I didn’t mention like hospitals and integrated care delivery networks) have to offer, and how these could be part of your long-term career adventure in healthcare and the life sciences.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content